144 related articles for article (PubMed ID: 37274614)
1. Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States.
Noharet-Koenig R; Lasota K; Faivre P; Langevin E
MDM Policy Pract; 2023; 8(1):23814683231174432. PubMed ID: 37274614
[TBL] [Abstract][Full Text] [Related]
2. Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review.
Bencina G; Fues Wahl H; Tsoumani E; Salomonsson S
Hum Vaccin Immunother; 2022 Nov; 18(5):2060017. PubMed ID: 35438039
[TBL] [Abstract][Full Text] [Related]
3. Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature.
Arya S; Norton N; Kaushik P; Brandtmüller A; Tsoumani E
Hum Vaccin Immunother; 2023 Dec; 19(3):2279394. PubMed ID: 38014651
[TBL] [Abstract][Full Text] [Related]
4. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India.
Ghia CJ; Horn EK; Rambhad G; Perdrizet J; Chitale R; Wasserman MD
Infect Dis Ther; 2021 Dec; 10(4):2271-2288. PubMed ID: 34313958
[TBL] [Abstract][Full Text] [Related]
8. Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States.
Perdrizet J; Horn EK; Hayford K; Grant L; Barry R; Huang L; McDade C; Wilson M
Infect Dis Ther; 2023 May; 12(5):1351-1364. PubMed ID: 37079175
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.
Wilson M; Wasserman M; Jadavi T; Postma M; Breton MC; Peloquin F; Earnshaw S; McDade C; Sings H; Farkouh R
Infect Dis Ther; 2018 Sep; 7(3):353-371. PubMed ID: 29934878
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
11. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.
Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R
Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428
[TBL] [Abstract][Full Text] [Related]
13. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
[TBL] [Abstract][Full Text] [Related]
15. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.
Hanquet G; Krizova P; Valentiner-Branth P; Ladhani SN; Nuorti JP; Lepoutre A; Mereckiene J; Knol M; Winje BA; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Slotved HC; Fry NK; Rinta-Kokko H; Varon E; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Latasa P; Castilla J; Smith A; Henriques-Normark B; Whittaker R; Pastore Celentano L; Savulescu C;
Thorax; 2019 May; 74(5):473-482. PubMed ID: 30355641
[TBL] [Abstract][Full Text] [Related]
16. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
Savulescu C; Krizova P; Lepoutre A; Mereckiene J; Vestrheim DF; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Varon E; Cotter S; Winje BA; Munoz-Almagro C; Garcia L; Castilla J; Smith A; Henriques-Normark B; Celentano LP; Hanquet G;
Lancet Respir Med; 2017 Aug; 5(8):648-656. PubMed ID: 28359798
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
19. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.
Ansaldi F; Pugh S; Amicizia D; Di Virgilio R; Trucchi C; Orsi A; Zollo A; Icardi G
Pathogens; 2020 Jan; 9(2):. PubMed ID: 31979079
[No Abstract] [Full Text] [Related]
20. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
